Intended for healthcare professionals

CCBYNC Open access

Rapid response to:

Research

Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database

BMJ 2011; 342 doi: https://doi.org/10.1136/bmj.d2139 (Published 21 April 2011) Cite this as: BMJ 2011;342:d2139

Rapid Response:

Serious questions to be answered

If it is true that there is an increased risk of VTE in users of drospirenone containing COCs compared to users of levonorgestrel containing COCs, it is very alarming.

These things should be investigated:

1) How was the evaluation of the studies presented 10 years ago and why did they advocate the drospirenone containing COCs as safer.

2) Why was the licensing of these COCs allowed, without full safety studies.

3) How come the Pharmaceutical Regulation Bureau of the European Union did not discover in time these serious side effects.

4) How come the Pharmaceutical Regulation Bureaus of the Member States of the European Union did not discover in time these serious side effects.

5) Why do pharmaceutical companies withdraw older and cheaper medicines to promote new and more expensive ones.

In my Country all COCs containing levonorgestrel have been withdrawn and there are only third-generation COCs available in Pharmacies and Hospitals!

Competing interests: No competing interests

04 May 2011
Stavros Saripanidis
Consultant in Obstetrics and Gyneacology in Greece
Private Sector, 55131